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Background:	 Finding	 the	 optimal	 duration	 of	 anticoagulant	 treatment	 following	 an	
acute	event	of	deep	vein	thrombosis	(DVT)	is	challenging.	Residual	venous	obstruction	
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1  | INTRODUCTION
The	optimal	management	 strategy	 for	 the	prevention	of	 recurrent	
	venous	thromboembolism	(VTE)	is	still	uncertain.	Venous	thrombo-
embolism	contributes	significantly	to	global	disease	burden.1	Within	




the	 burden	 of	 disease,1	 anticoagulation	 treatment,	 the	 mainstay	
of	VTE	 prevention,	 is	 accompanied	 by	 a	 significant	 risk	 of	 bleed-
ing	 complications.3	 Efficient	 prevention	 thus	 critically	 depends	on	
optimal	 assessment	 of	 recurrence	 risk	 in	 individual	 patients.	 Even	
though	a	number	of	clinical	criteria,	laboratory	assays,	and	even	im-
aging	tests	have	been	proposed	as	risk	factors	for	recurrent	VTE,4,5 










is	used	 in	 combination	with	other	diagnostic	 and	prognostic	 tools	
in	 a	management	 strategy.	 In	 particular,	 the	 effects	 of	 a	manage-





clinical	 problems	 in	 complex	 organisations.12	 CCPs	 aim	 to	 translate	
evidence-	based	medicine	 into	clinical	practice,	 improve	collaboration	
among	 multiple	 specialized	 care	 providers	 and	 standardize	 health	
care	procedures.13,14	CCPs	have	been	 introduced	for	patients	with	a	
variety	of	 clinical	 problems	 including	venous	 thromboembolism.15–19 
However,	knowledge	on	the	long-	term	effects	of	CCPs	on	clinical	out-
comes	of	patients	with	VTE	is	lacking.	The	present	investigation	aimed	
to	 investigate	 both	 the	 long-	term	 clinical	 outcomes	 in	 patients	with	
DVT	managed	in	a	defined	CCP	incorporating	the	presence	of	RVO	and	
also	to	determine	risk	 factors	 for	VTE	recurrence	 in	a	contemporary	
cohort	of	patients	with	proximal	DVT	managed	within	a	defined	CCP.
2  | METHODS
2.1 | Study design and population
The	 present	 study	 represents	 a	 observational	 health	 care	 manage-
ment	study	and	no	control	group	was	assessed.	Clinical	outcomes	of	
all	patients	that	were	treated	within	a	clinical	care	pathway	(CCP)	of	
the	 Maastricht	 University	 Medical	 Center	 (MUMC)	 between	 2003	
and	 2013	were	 investigated.	MUMC	 is	 the	 only	 tertiary	 hospital	 in	
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guidelines.	The	major	principles	are	 illustrated	 in	Figure	1.	Patients	
are	 assigned	 to	 three	 different	 categories:	 (i)	 patients	with	 a	 pro-
voked	DVT	 in	 the	course	of	a	 reversible	 risk	 factor	such	as	 recent	
surgery	are	assigned	to	three	months	of	anticoagulation	treatment;	
(ii)	 patients	with	 an	unprovoked	DVT	are	 assigned	 to	6	months	of	
anticoagulation	 therapy	 and	 extensive	 risk	 assessment;	 (iii)	 high-	
risk	 patients	 are	 assigned	 to	 an	 indefinite	 anticoagulant	 treatment	
regimen.	 “Provoked	DVT”	was	 defined	 as	DVT	with	 the	 presence	





elevated	D-	dimer,	 high	 factor	 VIII,	 known	 high-	risk	 thrombophilia,	
inflammation,	or	active	cancer.	High	risk	thrombophilia	were	defined	
as	protein	S	or	C	deficiency,	homozygous	factor	V-	Leiden	mutation,	
antithrombin	 deficiency,	 or	 antiphospholipid	 antibody	 syndrome.21 
Antithrombin	 deficiency	 was	 defined	 as	 functional	 antithrombin	






of	 elevated	D-	dimer,	 high	 factor	VIII,	 and	persistent	 elevated	CRP	
was	considered	for	risk	assessment	1	month	after	stop	anticoagula-
tion only.
Presence	of	RVO	at	 the	 time	of	planned	 treatment	discontin-
uation	is	the	primary	risk	factor	upon	which	treatment	duration	is	
further	tailored.	If	no	RVO	is	present	at	this	time	point,	anticoag-
ulation	 treatment	will	 be	 stopped.	 In	 the	 case	 of	 detected	 RVO,	
anticoagulation	will	be	prolonged	for	another	3	months	(provoked	
DVT),	or	6	months	(unprovoked),	respectively.	Treatment	will	only	
be	prolonged	once.	Deviations	 from	 the	protocol	 could	be	made	
at	 the	 discretion	 of	 the	 treating	 physician	 to	 address	 patients	
preferences.
2.4 | Assessment of RVO
RVO	 was	 assessed	 using	 compression	 ultrasound	 (CU)	 as	 previ-
ously described24	 and	 a	 protocol	 has	 been	 implemented	 for	 con-
ducting	 a	 series	 of	 standardized	 ultrasound	 measurements	 as	
follows.	Measurements	were	taken	at:	(i)	the	common	femoral	vein,	
just	 below	 the	 inguinal	 ligament,	 and	 (ii)	 at	 the	popliteal	 vein.	No	
iliacal	 or	 calf	 veins	were	 assessed.	 B-	mode	 images	were	 taken	 in	
a	 transverse	 plane.	 RVO	was	 defined	 according	 to	 the	 definition	
of	Prandoni	as	residual	vein	diameter	during	compression	of	more	
than 2 mm.24	Several	studies	confirmed	an	acceptable	accuracy	and	
inter-	observer	 reproducibility	 of	 this	 method24–27 and agreement 
between	observers	was	achieved	by	close	 teamwork	among	team	




A	 structured	 database	 was	 implemented.	 Outcome	 data	 were	 also	
documented	 as	 part	 of	 clinical	 routine.	After	 completion	 of	 2	years	
of	 follow-	up	 in	 the	 course	of	CCP,	 outcome	data	were	 additionally	
collected	over	 the	 course	of	 further	outpatient	 visits	 and	accessing	
MUMC	and	general	practitioner	records.
2.6 | Determination of laboratory tests
Laboratory	 data	were	 determined	 in	 a	 certified	MUMC+	 laboratory	
using	 established	methods	 as	 previously	 described.28	Venous	 blood	
samples	 were	 collected	 in	 commercially	 available	 tubes	 with	 and	
without	 citrate	 0.106	mol/l	 as	 appropriate	 following	 an	 established	
protocol	 to	 ensure	 adequate	 preanalytic	 conditions.	 Samples	 were	
centrifuged	according	 to	 recent	guidelines	 (10	minutes	at	1500	g	or	




Criteria for admission: 
- Proximal lower extremity DVT
- Diagnosed at MUMC between 1st June
2003 and 30th June 2013
- Aged 18 or older
Clinical care pathway started (n = 479)
Clinical care pathway completed (n = 474; 99%)
Moved abroad: n = 5
Extended observation period (n = 457; 94.7%) 
Lost to follow-up: n = 17 
Patients with proximal DVT
Provoked DVT
n = 179; 37.4%
RVT not present
(n = 125; 69.8%)
RVT not present
(n = 127; 59.4%)
RVT not present
(n = 23; 26.7%)
RVT present
(n = 45; 25.1%)
RVT present
(n = 80; 37.4%)
RVT present
(n = 19; 22.1%)
Unprovoked DVT
n = 214; 44.7%
High-risk
n = 86; 17.9%
3 months OAC 6 months OAC 6 months OAC 12 months OAC Indefinite OAC 








2.7 | Outcomes, predictor variables, and co- variables
We	 defined	 the	 time	 to	 recurrent	 VTE	 as	 the	 primary	 outcome.	
Recurrent	VTE	was	defined	as	objectively	confirmed	proximal	or	dis-
tal	DVT,	PE,	or	other	venous	thrombosis	as	determined	by	CU,	spi-









tively	 (Table	1).4,5,30–32	Periods	of	 oral	 anticoagulation	 administration	









ity	 rates	were	 reported	 for	 all	 subgroups.	Cumulative	 incidences	of	
recurrent	VTE	 in	 patients	with	 and	without	 risk	 factors	were	 com-
pared	using	Kaplan–Meier	curves	and	the	 log-	rank	test.	A	Cox	pro-
portional	hazards	model	was	used	to	calculate	associations	between	
















followed	 for	 a	median	of	 4.6	years	 equivalent	 to	 2231.2	 patient-	
years	(Table	1).	The	median	age	was	58.0	years	(inter-	quartile	range	
[IQR]	46.1,	71.1;	50.5%	of	the	patients	were	female	(n	=	242).	DVT	




nite	 in	 16.5%	 (n	=	79).	 All	 patients	 received	 vitamin	K	 antagonist	
therapy	 (predominantly	 acenocoumarol).	 RVO	was	 present	 in	 45	




Thirty	 seven	 recurrent	 VTE	 were	 observed	 within	 the	 first	 two	
years	of	CCP	follow-	up	and	64	VTE	during	the	extended	follow-	up.	














Subgroup	analyses	 revealed	higher	 incidence	 rates	 for	 the	 following	
risk	factors:	male	sex,	traveling	history,	inflammatory	disease,	elevated	






follow-	up),	 respectively.	 The	 highest	mortality	 rates	were	 observed	
among	 patients	 with	 active	 cancer	 (14.6	 or	 17.4	 per	 100	 patient-	
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Clinical care pathway (n = 479) Extended observation period (n = 474)






Age	(median,	IQR) 58.0	(46.1,	71.1) 0 58.0	(46.1,	71.0) 0
Females 242	(50.5) 0 239	(50.4) 0
Duration	of	anticoagulation	(mutually	exclusive	groups)
 3 months 75	(15.7) 0 75	(15.8) 0
	6	months 230	(48.0) 0 228	(48.10) 0
 12 months 95	(19.8) 0 95	(20.1) 0
	Indefinite 79	(16.5) 0 76	(16.0) 0
Provoking	risk	factors	(mutually	exclusive	groups)
	Provoked	by	surgeryc 95	(19.9) 0 95	(20.0) 0
	Non-	surgical	transient	risk	factorc 107	(22.3) 0 106	(22.4) 0
	Unprovoked	VTEc 265	(55.3) 0 261	(55.1) 0
 Active cancerc 12	(2.5) 0 12	(2.5) 0
Other	risk	factors
	Pregnancyd 6	(1.3) 0 6	(1.3) 0
	Contraceptive	use	at	the	time	of	thrombosisd 50	(10.4) 6 50	(10.6) 6
 Traveld 34	(7.1) 0 34	(7.2) 0
	Immobilizationd 40	(8.4) 6 39	(8.2) 6
	Inflammationd 64	(13.4) 7 63	(13.3) 7
	Previous	VTEd 91	(19.0) 0 90	(19.0) 0
	Cardiovascular	diseased 115	(24.0) 5 115	(24.3) 5
	Heart	failured 6	(1.3) 6 6	(1.3) 6
	Known	thrombophiliad 19	(4.0) 7 18	(3.8) 7
	Venous	insufficiencyd 31	(6.5) 8 31	(6.5) 8
	Varicosisd 22	(4.6) 177 22	(4.6) 173
 Residual thrombosisd,e 144	(30.1) 60 141	(29.8) 58
	Smokingd 107	(22.3) 29 106	(22.4) 26
 Family historyd 140	(29.2) 14 138	(29.1) 14
Risk	factors	not	assessed	at	baseline
	Elevated	D-	dimerd,f 112	(23.4) 122 112	(23.6) 119
	Elevated	CRPd,f 109	(22.8) 174 109	(23.0) 171
	Elevated	FVIIId& 65	(13.6) 157 65	(13.7) 153




















1	month	 after	 anticoagulant	 treatment	 was	 stopped,	 male	 sex,	 and	
high	factor	VIII.	We	also	documented	that	99%	of	patients	diagnosed	
with	proximal	DVT	and	treated	within	the	CCP	completed	the	2	year	












served.17 There have been several other investigations studying small 
cohorts,	 but	 few	 or	 no	 clinical	 outcomes	were	 reported.17,35–38	 In	
contrast,	we	studied	the	long-	term	clinical	outcomes	in	large	cohort	
of	patients	treated	within	a	defined	CCP	considering	risk	assessment	






well as in others.43,44	In	contrast	to	earlier	cohorts,	risk	of	recurrence	
was	very	low	in	patients	taking	estrogen	containing	contraceptives	at	
the	time	of	thrombosis.45	This	difference	is	most	probably	reflected	
by	 the	 increased	 awareness	 of	 the	 associated	 risk	 and	 the	 subse-
quent	strict	avoidance	of	estrogen-	containing	drugs	in	patients	that	
have	suffered	from	VTE.	 In	 line	with	previous	data,	high	factor	VIII	
was associated with recurrent thromboembolism.46,47	 In	 addition,	






patients	and	recurrent	events	were	 limited,	resulting	 in	 imprecise	
estimations	 for	 some	 of	 the	more	 infrequent	 predictor	 variables	
or	those	with	a	smaller	effect.	This	effect	was	intensified	by	a	rel-
evant	 number	 of	missing	values	with	 regard	 to	 the	variables	 not	
assessed	at	baseline.	However,	we	did	not	find	apparent	discrepan-
cies	in	sensitivity	analyses	(eg,	after	multiple	imputation).	Another	
limitation	 is	 that	 only	 very	 few	 patients	with	 active	 cancer	were	
included	in	our	cohort.	Thus,	the	results	of	our	investigation	can-
not	be	extended	to	this	specific	population.49 Also concerning the 
efficacy	of	the	management	strategy	some	limitations	have	to	be	
considered.	We	were	 not	 able	 to	 record	 bleeding	 events	 due	 to	
organizational	 reasons.	Therefore,	 our	 conclusions	 are	 limited	 to	
the	 efficacy	 of	 the	 CCP.	Moreover,	we	 did	 not	 implement	 a	 for-
mal	assessment	of	the	compliance	with	the	CCP.	The	risk	of	rele-
vant	protocol-	deviations	is	however	estimated	to	be	low	because	
the	 duration	 of	 anticoagulation	 fits	well	with	 the	 risk	 categories	







this	 reflects	 clinical	 practice	 of	 a	 clinical	 care	 pathway.	 Another	
limitation	is	that	we	did	not	record	if	the	recurrent	event	was	pro-
voked	or	unprovoked.






































95% CI Failure function





In	 conclusion,	 in	 this	 study	we	 have	 demonstrated	 that	 long-	term	









Incidence rate (95% CI) 
per 100 patient- years Events frequency
Observation time 
patient- years
Incidence rate (95% CI) 
per 100 patient- years








6 192 3.1	(1.4,	7.0) 11 519 2.1	(1.2,	3.8)
Unprovoked	VTE 29 478 6.1	(4.2,	8.7) 47 1186 4.0	(3.0,	5.3)
Active cancer 0 21 N/A 0 52 N/A
Other	risk	factors
Male	sex 26 429 6.1	(4.1,	8.9) 41 1042 3.9	(2.9,	5.3)
Female sex 11 447 2.5	(1.4,	4.4) 23 1190 1.9	(1.3,	2.9)




0 94 N/A 1 270 0.4	(0.0,	2.6)
Travel 4 60 6.6	(2.5,	17.7) 8 175 4.6	(2.2,	3.7)
Immobilization 2 69 2.9	(0.7,	11.5) 2 168 1.2	(0.3,	4.8)
Inflammation 8 117 6.8	(0.3,	13.7) 15 317 4.7	(2.9,	7.9)
Previous	VTE 2 175 1.1	(0.3,	4.6) 10 492 2.0	(1.1,	3.8)
Cardiovascular	
disease
10 209 4.8	(2.6,	8.9) 17 467 3.6	(2.3,	5.9)
Heart	failure 0 12 N/A 1 33 3.0	(0.4,	21.6)
Known	
thrombophilia
0 36 N/A 1 91 1.1	(0.2,	7.8)
Venous	
insufficiency
0 59 N/A 0 106 N/A
Varicose	veins 1 43 2.3	(0.3,	16.4) 3 139 2.2	(0.7,	6.7)
Smoking 7 200 3.5	(1.7,	7.4) 13 524 2.5	(1.4,	4.3)




12 270 4.4	(2.5,	7.8) 22 689 3.2	(2.1,	4.8)
Elevated	Villalta	
scoreb,d
6 148 4.0	(1.8,	9.0) 14 362 3.9	(2.3,	6.5)
Elevated	D-	dimerc 17 197 8.6	(5.4,	13.9) 26 514 5.1	(3.4,	7.4)
High	factor	VIIIc 9 120 7.5	(3.9,	14.5) 17 329 5.2	(3.2,	8.3)
Elevated	CRPc 11 201 5.5	(3.0,	9.9) 22 537 4.1	(2.7,	6.2)
aAssessed	one	week	before	intended	cessation	of	anticoagulation	treatment.
bAssessed at six months.
cAssessed	one	month	after	stopping	OAC.
d≥5	points.
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wrote	 the	manuscript.	MN	 developed	 the	 analysis	 plan	 and	 con-
ducted	the	statistical	analysis.	ATC	developed	and	implemented	the	






























265 237 202 161 137
107 97 84 65 62




























































































































214 185 138 123 105
225 194 159 139 121
Male Female
Number at risk
Number at risk Number at risk
Number at risk
112 85 71 60 52D-dimer positive
D-dimer negative 245 236 210 176 164 142
D-dimer positive D-dimer negative
Contraceptives 50 46 43
















High factor VIII Others
33
153
Inflammation 64 59 51 45 32
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